VRDN / Viridian Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

As filed with the Securities and Exchange Commission on September 5, 2025.

S-3ASR As filed with the Securities and Exchange Commission on September 5, 2025. Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viridian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdiction of incorporation or org

Security Type

Calculation of Filing Fee Tables S-3 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw

As filed with the Securities and Exchange Commission on August 6, 2025

S-8 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 VIRIDIAN THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

Registrant’s 2025 Employee Stock Purchase Plan (Incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed on August 6, 2025 (File No. 001-36483)).

Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: April 23, 2025 Approved by the Stockholders: June 20, 2025 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a seri

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on trac

EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 - - Breakthrough Therapy Designation (BTD) for veligrotug announced in M

Filing Fee Table

Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Kissei

EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan - - Viridian to receive an upfront pay

Viridian Therapeutics, Inc. Amended and Restated 20

Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 23, 2025 APPROVED BY THE STOCKHOLDERS: June 20, 2025 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with veligrotug in THRIVE who were proptosis responders a

Exhibit 99.1 Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 - - Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligib

This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might

EX-99.2 THRIVE in Active TED 52-Week Follow-Up Update (May 20, 2025) Exhibit 99.2 This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,”

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commer

EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 VIRIDIAN THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission

Radhika Tripuraneni Employment Agreement, dated February 23, 2025.

Exhibit 10.3 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of February 23, 2025 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 103A, Waltham, MA 02453 (the “Company”), and Radhika Tripuraneni, an individual residing at 12 Sunset Court, Menlo Park CA 94025 (“

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER

Separation Agreement and Consulting Agreement, dated as of March 1, 2025, by and between the Registrant and Thomas Ciulla.

Exhibit 10.1 March 1, 2025 By Email Thomas Ciulla, MD 15977 Bridgewater Club Blvd Carmel, IN 46033 Dear Tom: This letter agreement (“Agreement”) confirms the terms of your separation without cause from Viridian Therapeutics, Inc. (“Viridian” or the “Company”).1 Unless you rescind your assent as set forth in Section 4(vii) below, this Agreement shall be effective, final and binding upon the expirat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Mr. Ajer was most recently Chief Commercial Officer at BioMarin -

Exhibit 99.1 Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Waltham, Mass., April 7, 2025 — Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

$300,000,000 Viridian Therapeutics, Inc. Common Stock

424B5 1 d126976d424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267351 PROSPECTUS SUPPLEMENT (to Prospectus dated September 9, 2022) $300,000,000 Viridian Therapeutics, Inc. Common Stock We have entered into an Open Market Sale AgreementSM (the “Sale Agreement”), dated March 3, 2025, with Jefferies LLC (“Jefferies”), relating to shares of our common stock offered by this pros

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Calculation of Filing Fee Tables 424 (b)(5) (Form Type) Viridian Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424 (b)(5) (Form Type) Viridian Therapeutics, Inc.

Open Market Sale Agreement, dated March 3, 2025 by and between Viridian Therapeutics, Inc. and Jefferies LLC.

Exhibit 1.1 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM March 3, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of t

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as material terms of our second restated certificate of incorporation (“certificate of incorporation”), fourth amended and restated bylaws (“bylaws”) and certain provisions of Delaware law.

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts

Insider Trading Policy

Exhibit 19 INSIDER TRADING POLICY (Approved February 12, 2025) I.INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such Material Nonpublic Information from disclosing this information to others who trade. Trading w

Filing Fee Table

Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to be

Amendment to Stephen Mahoney Employment Agreement, dated February

Exhibit 10.38 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Steve Mahoney (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated October 27, 2023 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall have the

Amendment to Thomas Beetham Employment Agreement, dated February

Exhibit 10.39 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Thomas Beetham (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated October 27, 2023 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall have the

As filed with the Securities and Exchange Commission on March 3, 2025

As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

Amendment to Jennifer Tousignant Employment Agreement, dated February

Exhibit 10.41 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Jennifer Tousignant (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated January 10, 2024 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall hav

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP

Amendment to Seth Harmon Employment Agreement, dated February

Exhibit 10.40 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Seth Harmon (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated April 24, 2023, as amended on September 28, 2023 (the “Agreement”). Capitalized terms used herein but not oth

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye dis

EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

JOINT FILING AGREEMENT

EX-99.1 2 ex-99-02142025110232.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Viridian Therapeutics, Inc. and further agree that t

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2,

Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global pha

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

VRDN / Viridian Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2428137d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Che

VRDN / Viridian Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d912234dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen

VRDN / Viridian Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm2427604d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this stateme

VRDN / Viridian Therapeutics, Inc. / Venrock Opportunities Fund, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2428137d21sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

Amended and Restated License Agreement by and between Registrant and Paragon Therapeutics, Inc. dated as of September 20, 2024.

Exhibit 10.2 [***] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is entered into and effective as of September 20, 2024 (the “A&R Effective Date”)

Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of

Exhibit 10.1 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this "Amendment") is made as of the 19th of September, 2024 (the “Effective Date”) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (“Landlord”), and VIRIDIAN THERAPEUTICS, INC., a Dela

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,”

Corporate Presentation November 2024 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report t

Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003,

VRDN / Viridian Therapeutics, Inc. / STATE STREET CORP Passive Investment

SC 13G/A 1 ViridianTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIRIDIAN THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the

VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment

SC 13D/A 1 tm2424267d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400

Calculation of Filing Fee Tables (Form Type) Viridian Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Viridian Therapeutics, Inc.

$225,000,000 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock

424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267351 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) $225,000,000 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock We are offering 10,666,600 shares of our common stock, par value $0.01 per share (“common stock”), and, in lieu of shares of our common stock to certain investors, 20,000 s

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com

Underwriting Agreement, by and among the Company and the Representatives, dated as of September 11, 2024

Exhibit 1.1 Execution Version 10,666,600 Shares of Common Stock  20,000 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT September 11, 2024 JEFFERIES LLC GOLDMAN SACHS & CO. LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o GOLDMAN SACHS & CO. LLC 200 Wes

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com

$150,000,000 Shares of Common Stock Shares of Series B Preferred Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267351 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer

Filing Fee Table

Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type  Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to

As filed with the Securities and Exchange Commission on August 12, 2024

S-8 As filed with the Securities and Exchange Commission on August 12, 2024 Registration No.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout in September 2024 - - THRIVE-2

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial in chronic TED topline readout expected year-end 2024; enrollment completed in July and exceeded

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

Fourth Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of April 8, 2024.

Exhibit 10.1 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Amendment") is made as of the 8th day of April, 2024 (the “Effective Date”) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (“Landlord”), and VIRIDIAN THERAPEUTICS, INC., a Del

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

Exhibit 99.1 Corporate Presentation July 2024 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Registrant’s Amended & Restated 2016 Equity Incentive Plan (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 20, 2024 (File No. 001-36483)).

EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 19, 2024 APPROVED BY THE STOCKHOLDERS: June 17, 2024 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topl

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒       Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA 19428 (267

Filing Fee Table

Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type  Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to be

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

2016 Amended and Restated Employee Stock Purchase Plan.

Exhibit 10.18 Viridian Therapeutics, Inc. 2016 Amended and Restated Employee Stock Purchase Plan Adopted by the Board of Directors: November 30, 2016 Approved by the Stockholders: February 10, 2017 Amended and Restated by the Board of Directors: March 30, 2023 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant (as of February 27, 2024) Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts

Lara Meisner Employment Agreement, dated May 11, 2023.

Exhibit 10.6 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of May 11, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Lara Meisner, an individual residing at 11 Thornton Road, Needham, MA 02492 (“Executive”). (

Jennifer Tousignant Employment Agreement, dated January 10, 2024.

Exhibit 10.12 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of January 10, 2024 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Jennifer Tousignant, an individual residing at 29 Wheelock Road, Sutton, MA 01590 (“Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP

Form of Indemnity Agreement between the Registrant and each of its directors and executive officers.

Exhibit 10.2 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of [●] between Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Highly competent persons have become more reluctant to serve corporations as directors or officers or in other capacities unless they are provided with adequate protection through

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and year-end 2024, respectively - -

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and year-end 2024, respectively - - Subcutaneous VRDN-003 pivotal program in thyroid eye disease expected to start mid-year 2024 pending regulatory authority alignment, as p

Exhibit 4.5

Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as material terms of our second restated certificate of incorporation (“certificate of incorporation”), fourth amended and restated bylaws (“bylaws”) and certain provisions of Delaware law.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

Viridian Therapeutics, Inc. Incentive Compensation Clawback Policy.

Exhibit 97.1 INCENTIVE COMPENSATION CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of Viridian Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any su

Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan.

Exhibit 10.16 Viridian Therapeutics, INC. Amended and Restated 2016 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Viridian Therapeutics, Inc. (the “Company”), pursuant to its Amended and Restated 2016 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the term

Thomas Ciulla Employment Agreement, dated January 12, 2023.

Exhibit 10.9 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 12, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Ciulla, an individual residing at 15977 Bridgewater Club Blvd, Carmel, IN 46033 (

Seth Harmon Employment Agreement, dated April 24, 2023.

Exhibit 10.10 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of April 24, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, an individual residing at 74 Chebacco Rd, Hamilton, MA 01982 (“Executive”).

Amendment to Seth Harmon Employment Agreement, dated September 28, 2023.

Exhibit 10.11 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (“Amendment”) is made as of September 28, 2023 by and between Viridian Therapeutics Inc., a Delaware corporation with a principal business address at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, with an address at 74 Chebacco Road, Hamilton, MA 01982 (“Executive”). WHEREAS, the Company and the Exe

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan.

Exhibit 10.17 VIRIDIAN THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2016 AMENDED AND RESTATED EQUITY INCENTIVE PLAN) Viridian Therapeutics, Inc. (the “Company”), pursuant to its 2016 Amended and Restated Equity Incentive Plan (the “Plan”), hereby awards to Participant the number of restricted stock units set forth below (“Award”). This Award is subject to all of the terms and conditions

VRDN / Viridian Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm246235d28sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check

VRDN / Viridian Therapeutics, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

VRDN / Viridian Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm245955d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement

VRDN / Viridian Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga307422vrdn02142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 p

VRDN / Viridian Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

VRDN / Viridian Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02227-viridiantherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Viridian Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92790C104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

VRDN / Viridian Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.  )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) January 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

AGREEMENT

EX-99.1 2 d744744dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: January 29, 20

VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment

SC 13D/A 1 d75782dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 Wes

Underwriting Agreement, by and among the Company and the Representatives, dated as of January 17, 2024

Exhibit 1.1 Execution Version 7,142,858 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT January 17, 2024 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Introductory. Viridian

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 VIRIDIAN THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi

Calculation of Filing Fee Tables (Form Type) Viridian Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Viridian Therapeutics, Inc.

7,142,858 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267351 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) 7,142,858 Shares of Common Stock We are offering 7,142,858 shares of our common stock, par value $0.01 per share (“common stock”). Our common stock is traded on The Nasdaq Capital Market under the symbol “VRDN.” On January 17, 2024, the last reported sa

Shares of Common Stock Shares of Series B Preferred Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 VIRIDIAN THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference - VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye di

EX-99.1 Exhibit 99.1 Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference - VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease (TED), respectively - - Subcutaneous VRDN-003 pivotal study in TED anticipated to start in mid-2024, pending alignment with

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease - VRDN-003 clini

EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease - VRDN-003 clinical data exceeded expectations with extended half-life of 40-50 days, 4-5x longer than VRDN-001, supporting a potential best-in-c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 VIRIDIAN THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

EX-99.2 Exhibit 99.2 Subcutaneous IGF-1R Program Selection December 18, 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,

Fourth Amended and Restated Bylaws of the Registrant, effective as of December 15, 2023.

EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both wi

VRDN / Viridian Therapeutics Inc / Venrock Opportunities Fund, L.P. - SC 13G Passive Investment

SC 13G 1 tm2332269d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) November 1, 2023 (Date of Event Which Requires Filing of this Statement) Che

As filed with the Securities and Exchange Commission on November 30, 2023

S-3ASR As filed with the Securities and Exchange Commission on November 30, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Viridian Therapeutics, Inc.

Form of Registration Rights Agreement, by and among the company and the Purchasers signatory thereto.

EX-4.2 Exhibit 4.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of , 2023, by and among Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Secur

Form of Securities Purchase Agreement, by and among the company and the Purchasers signatory thereto.

EX-10.1 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of , 2023, by and among VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purch

Thomas Beetham Employment Agreement, dated October 27, 2023.

VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Beetham (“Executive”). (Executive and the Company collectively the “Parties” and each of the P

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinic

Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 - - Timing for the selection of lead subcutaneous TED program is on track for the e

, effective as of November 1,

Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and

Stephen Mahoney Employment Agreement, dated October 27, 2023

VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Steve Mahoney (“Executive”). (Executive and the Company collectively the “Parties” and each of the Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 VIRIDIAN THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

First Amendment to Loan and Security Agreement, dated as of August 7, 2023, among the Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to time party thereto and Hercules Capital, Inc., as Agent.

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN

VRDN / Viridian Therapeutics Inc / Fairmount Funds Management LLC - SC 13D/A Activist Investment

SC 13D/A 1 d563332dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 We

Third Amended and Restated Bylaws of the Company, effective as of November 1, 2023.

Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within an

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing – Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in

Exhibit 99.1 Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing – Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain on

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi

Registration Rights Agreement, dated October 30, 2023, by and between the Company and the Purchasers signatory thereto.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of October 30, 2023, by and among Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie

Securities Purchase Agreement, dated October 30, 2023, by and between the Company and the Purchasers signatory thereto.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 30, 2023, by and among VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser i

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 VIRIDIAN THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm

As filed with the Securities and Exchange Commission on August 8, 2023

S-8 As filed with the Securities and Exchange Commission on August 8, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA

Filing Fee Table

EX-FILING FEES Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe

As filed with the Securities and Exchange Commission on July 24, 2023

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on July 24, 2023 Registration No.

Filing Fee Table.

Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Viridian Therapeutics, Inc.

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

EX-99.1 Exhibit 99.1 ® Corporate Overview July 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, anticipate, believe, continue, could, estimate, expect, intend, may, might, plan,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week

EX-99.1 Exhibit 99.1 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED ame

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

EX-99.2 VRDN-001 Phase 1/2 results in patients with chronic TED July 2023 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could,"

Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan

EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 10, 2023 APPROVED BY THE STOCKHOLDERS: June 14, 2023 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

VRDN / Viridian Therapeutics Inc / Atlas Venture Fund VII L P - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 92790C104 (CUSIP Number) Accomplice Attention: Frank Cast

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

VRDN / Viridian Therapeutics Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) May 1, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of

EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership te

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 VIRIDIAN THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

Filing Fee Table

EX-FILING FEES Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe

Form of Inducement Restricted Stock Unit Agreement.

EX-99.4 Exhibit 99.4 VIRIDIAN THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2016 AMENDED AND RESTATED EQUITY INCENTIVE PLAN) Viridian Therapeutics, Inc. (the “Company”), pursuant to its 2016 Amended and Restated Equity Incentive Plan (the “Plan”), hereby awards to Participant the number of restricted stock units set forth below (“Award”). This Award is subject to all of the terms and cond

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 VIRIDIAN THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

Power of Attorney (included on signature page hereto).

S-8 As filed with the Securities and Exchange Commission on March 10, 2023 Registration No.

Exhibit 4.5

Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as other material terms of our second restated certificate of incorporation (“certificate of incorporation”) and second amended and restated bylaws (“bylaws”) and certain provisions of Dela

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant (as of March 9, 2023) Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First p

EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2024 - - Initial results from

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 VIRIDIAN THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

VRDN / Viridian Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

VRDN / Viridian Therapeutics Inc / Cormorant Asset Management, LP Passive Investment

SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

VRDN / Viridian Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Numbe

VRDN / Viridian Therapeutics Inc / Vivo Opportunity, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

VRDN / Viridian Therapeutics Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm236584d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check

VRDN / Viridian Therapeutics Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm236410d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement)

VRDN / Viridian Therapeutics Inc / TCG Crossover GP I, LLC - AMENDMENT NO. 3 Passive Investment

SC 13G/A 1 viri213231sc13ga3.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement)

VRDN / Viridian Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv02197-viridiantherapeutics.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Viridian Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92790C104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p

Jonathan Violin General Release and Separation and Consulting Agreement, dated February 6, 2023

EX-10.2 Exhibit 10.2 221 Crescent Street Suite 401 Waltham, MA 02453 617-272-4600 Viridiantherapeutics.com GENERAL RELEASE AND SEPARATION AND CONSULTING AGREEMENT This General Release and Separation and Consulting Agreement (this “Agreement”) is made this 6th day of February 2023 (the “Separation Date”) by and between Viridian Therapeutics, a Delaware corporation (the “Company”), and Jonathan Viol

Scott Myers Employment Agreement, dated December 29, 2022

EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of December 29, 2022 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation, located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Scott Myers, an individual residing at 160 Waverly Way, Kirkland, WA 98033 (“E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 VIRIDIAN THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi

Viridian Appoints Scott Myers as President and Chief Executive Officer - Transition highlights Viridian’s progression towards becoming a fully-integrated biopharmaceutical company –

EX-99.1 Exhibit 99.1 NEWS RELEASE Viridian Appoints Scott Myers as President and Chief Executive Officer - Transition highlights Viridian’s progression towards becoming a fully-integrated biopharmaceutical company – Waltham, Mass. — February 6, 2023 — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for

VRDN / Viridian Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92790C104 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate t

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

VRDN-001 3 mg/kg results in patients with TED January 2023 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "ex

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally cons

EX-99.1 2 d427009dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated patients, 6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN

Third Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of July 29, 2022.

Final THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this "Amendment") is made as of the 29th day of July, 2022 (the ?Effective Date?) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc.

Open Market Sale Agreement, dated as of September 9, 2022 by and between the Registrant and Jefferies LLC

S-3ASR 1 d347132ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 9, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viridian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (

Form of Debt Indenture.

Exhibit 4.3 VIRIDIAN THERAPEUTICS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06

, dated as of September 9, 2022 by and between the Registrant and Jefferies LLC.

EX-1.2 2 d347132dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 9, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 Registration Statement under the Securities Act of 1933 (Form Type) Viridian Therapeutics, Inc.

Underwriting Agreement by and among the Company and the Representatives, dated as of August 16, 2022

Exhibit 1.1 9,627,640 Shares of Common Stock 28,084 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT August 16, 2022 JEFFERIES LLC SVB SECURITIES LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

VRDN / Viridian Therapeutics Inc / Fairmount Funds Management LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive Suite 400 West Conshohocken, PA 19428 (267) 262-5300

9,627,640 Shares of Common Stock 28,084 Shares of Series B Preferred Stock Viridian Therapeutics, Inc.

424B5 1 d294990d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-260859 PROSPECTUS SUPPLEMENT (To Prospectus dated November 17, 2021) 9,627,640 Shares of Common Stock 28,084 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. We are offering 9,627,640 shares of our common stock, and, for certain investors, 28,084 shares of our Series B no

PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED NOVEMBER 17, 2021

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260859 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED NOVEMBER 17, 2021 This Prospectus Supplement No. 1 supplements and amends the prospectus dated November 17, 2021 (the ?Prospectus?), covering the offering, issuance and sale of up to a maximum aggregate offering price of $75,000,000 (the ?Maximum Offering Price?) of our common stock that ma

Form of Inducement Stock Option Agreement

Exhibit 99.2 VIRIDIAN THERAPEUTICS, INC. GRANT NOTICE FOR INDUCEMENT AWARD NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, Viridian Therapeutics, Inc. (the ?Company?), hereby grants to Participant named below the non-qualified stock option (the ?Option?) to purchase any part or all of the number of shares of common stock (the ?Common Stock?), that are covered by this Option, as spe

Registrant’s Amended and Restated 2016 Equity Incentive Plan.

Exhibit 99.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 18, 2022 APPROVED BY THE STOCKHOLDERS: June 8, 2022 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended as to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentiv

Filing Fee Table

Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to be

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

As filed with the Securities and Exchange Commission on August 15, 2022

S-8 POS 1 d383850ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. 333-250906 Registration No. 333-216112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified

As filed with the Securities and Exchange Commission on August 15, 2022

As filed with the Securities and Exchange Commission on August 15, 2022 Registration No.

As filed with the Securities and Exchange Commission on August 15, 2022

S-8 POS 1 d383850ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. 333-250906 Registration No. 333-216112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified

Viridian Therapeutics, Inc. Amended & Restated 2016 Equity Incentive

VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 18, 2022 APPROVED BY THE STOCKHOLDERS: June 8, 2022 1.GENERAL. (a)Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended as to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan, as amen

Second Amendment to Lease by and between the Registrant and Watch City Ventures MT, LLC dated as of April 13, 2022.

Exhibit 10.2 SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this "Amendment") is made as of the 13th day of April, 2022 (the ?Effective Date?) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (?Landlord?), and VIRIDIAN THERAPEUTICS, INC., a De

SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT DATED AUGUST 15, 2022

Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/

Exhibit 99.4 NEWS RELEASE Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/kg VRDN-001 - - Proptosis response achieved by 83% of patients with a mean reduction of 2.4mm from baseline - - Clinical Act

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA

VIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES - Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) - - VRDN-002 achieved a su

Exhibit 99.1 VIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES - Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) - - VRDN-002 achieved a substantially extended half-life of 30-40 days in healthy volunteers with a sustained IGF-1 response and a favorable safety and tolerabilit

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

Exhibit 99.2 Corporate Presentation August 2022 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, pot

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but

Exhibit 99.3 VRDN-001 & VRDN-002 initial clinical data August 15, 2022 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, anticipate, believe, continue, could, estimate, expect, intend

VRDN / Viridian Therapeutics Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

VIRIDIAN THERAPEUTICS APPOINTS CARRIE MELVIN AS CHIEF OPERATING OFFICER

Exhibit 99.1 NEWS RELEASE VIRIDIAN THERAPEUTICS APPOINTS CARRIE MELVIN AS CHIEF OPERATING OFFICER WALTHAM, Mass., June 23, 2022 ? Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created posit

Carrie Melvin Employment Agreement, dated May 25, 2022

EX-10.1 2 d318381dex101.htm EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of May 25, 2022 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and Carrie L. Melvin (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referre

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio

VRDN / Viridian Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92790C104 (CUSIP Number) MAY 26, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi

VRDN / Viridian Therapeutics Inc / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER

Amended and Restated Bylaws of the Registrant, effective as of May 11, 2022.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01.Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the ?Corporation?) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02.Other Offices. The Corporation may also have offices at such other places both within and without

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements relating to Viridian Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic cand

Exhibit 99.2 Viridian Therapeutics May 2022 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements relating to Viridian Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulatory appro

VIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES — Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of conce

Exhibit 99.1 VIRIDIAN THERAPEUTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES ? Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022 ? ? Interim results for VRDN-001 in healthy volunteers show saturation of IGF-1 response at

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 d353949ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 d353949ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us

Loan and Security Agreement, dated as of April 1, 2022, among the Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to time party thereto and Hercules Capital, Inc., as Agent.

EXHIBIT 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of April 1, 2022 and is ent

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP

Form of Inducement Stock Option Agreement (Incorporated herein by reference to Exhibit 99.3 to the Registrant’s Registration Statement on Form S-8 filed on March 11, 2022 (File No. 333-263490)).

Exhibit 99.3 VIRIDIAN THERAPEUTICS, INC. GRANT NOTICE FOR INDUCEMENT AWARD NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, Viridian Therapeutics, Inc. (the ?Company?), hereby grants to Participant named below the non-qualified stock option (the ?Option?) to purchase any part or all of the number of shares of common stock (the ?Common Stock?), that are covered by this Option, as spe

Subscription Agreement, by and between the Registrant and Xencor, dated as of December 2, 2021.

Exhibit 10.4 SUBSCRIPTION AGREEMENT This Subscription Agreement (this ?Agreement?), dated December 2, 2021, is by and between Viridian Therapeutics, Inc., a Delaware corporation (the ?Company?) and Xencor, Inc., a Delaware corporation (?Subscriber?). WHEREAS, simultaneously with the execution of this Agreement, the Company and Subscriber are executing a technology license agreement (the ?License A

Filing Fee Table

EX-FILING FEES 5 d319693dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration F

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant (as of March 11, 2022) Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.?.r.l. Luxembourg Viridian Securities Corporation Massachusetts

Second Restated Certificate of Incorporation of the Registrant, effective as of March 9, 2022

Exhibit 3.1 SECOND RESTATED CERTIFICATE OF INCORPORATION OF VIRIDIAN THERAPEUTICS, INC. Viridian Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), DOES HEREBY CERTIFY: 1. That the name of this Corporation is Viridian Therapeutics, Inc., and that this Corporation was originally incorpo

As filed with the Securities and Exchange Commission on March 11, 2022

As filed with the Securities and Exchange Commission on March 11, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss

VIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES — Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top l

Exhibit 99.1 VIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES ? Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 ? ? VRDN-002, a distinct IGF-1R antibody incorporating validated half-life extens

VRDN / Viridian Therapeutics Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate th

VRDN / Viridian Therapeutics Inc / CITADEL ADVISORS LLC - VIRIDIAN THERAPEUTICS, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (the ?Shares?) (Title of Class of Securities) 92790C10

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

VRDN / Viridian Therapeutics Inc / Logos Global Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

VRDN / Viridian Therapeutics Inc / D. E. SHAW & CO, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant

VRDN / Viridian Therapeutics Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule

JOINT FILING AGREEMENT

Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

VRDN / Viridian Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - VIRIDIAN THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 tm225316d8sc13ga.htm VIRIDIAN THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fi

VRDN / Viridian Therapeutics Inc / Cormorant Asset Management, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

VRDN / Viridian Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) Decembe

VRDN / Viridian Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT # 2 Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Viridian Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.01 Par Va